🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "huge turning point" in the battle against superbug strains of the infection, according to health experts.

A Worldwide Health Concern

Gonorrhoea infections are increasing around the world, with figures suggesting in excess of 82 million infections each year. Notably increased rates are observed in the African continent and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary step in the context of growing infection rates, the spread of superbugs and the highly restricted available drugs currently available.”

Medical experts are deeply concerned about the surge in treatment-resistant strains. The global health body has designated it as a "priority pathogen". A tracking program revealed that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Therapies Secure Clearance

One new antibiotic, also known as a brand name, was approved by the US FDA in December for use against gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Researchers believe that focused deployment of this new drug will help delay the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GSK, gained clearance in close succession. This medication, which is employed against UTIs, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin was the result of a innovative non-profit model for drug creation. The charitable organization GARDP worked alongside the pharmaceutical company Innoviva to see it through.

“This authorization signifies a significant shift in the treatment of highly resistant gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Testing Outcomes and Global Access

According to data detailed in a prominent scientific publication, the new drug cured more than 90% of genital gonorrhoea infections. This puts it on an equal footing with the existing first-line therapy, which involves a dual-drug approach. The trial included hundreds of volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, the non-profit has the rights to register and commercialise the drug in numerous developing nations.

Clinicians on the front lines have expressed optimism. Having a easy-to-administer therapy like this is hailed as a "critical tool" for managing the epidemic. This is viewed as crucial to lessen the impact of the illness for patients and to prevent the spread of highly drug-resistant gonorrhoea globally.